Claims
- 1. A substance for reducing non-specific interactions in immunoassays, comprising a protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H or PO.sub.3 H.sub.2 groups.
- 2. The substance according to claim 1, wherein the albumin is bovine serum albumin.
- 3. The substance according to claim 1, wherein R is a methyl group or a --CH.sub.2 --CH.sub.2 --COOH group.
- 4. The substance according to claim 1, wherein the protein aggregate is chemically aggregated with homo- or heterobifunctional linkers.
- 5. The substance according to claim 1, wherein the protein aggregate is thermally aggregated.
- 6. The substance according to claim 5, wherein the substance is thermally aggregated acetylated or succinylated bovine serum albumin.
- 7. The substance according to claim 1, wherein the particle size of the acylated protein aggregate ranges between 10 and 200 nm.
- 8. The substance according to claim 7, wherein the particle size ranges between 20-50 nm.
- 9. An interference-reducing reagent for reducing non-specific interactions in immunoassays, comprising a buffer and a protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H or PO.sub.3 H.sub.2 groups wherein said protein aggregate is an aggregate of albumin.
- 10. The interference-reducing reagent according to claim 9, wherein the buffer has a pH value between 4 and 9.
- 11. A specific binding reagent for immunoassays comprising a binding partner of a specific binding pair and a protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H or PO.sub.3 H.sub.2 groups wherein said protein aggregate is an aggregate of albumin.
- 12. The specific binding reagent according to claim 11, wherein the binding partner is a labeled or biotinylated binding partner.
- 13. The specific binding reagent according to claim 11, wherein the binding partner is an antigen, antibody, or antibody fragment.
- 14. The specific binding reagent according to claim 13, wherein the binding partner is an antibody or antibody fragment with an enzymatic or electrochemiluminescent label.
- 15. A method for determining the presence of an immunological ligand in a sample, wherein the method reduces non-specific interactions, comprising the steps of
- contacting a sample to be tested for a ligand with (a) at least one protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H or PO.sub.3 H.sub.2 groups wherein said protein aggregate is an aggregate of albumin; and (b) at least one specific binding partner of a specific binding pair, wherein the at least one binding partner is labeled, to form a detectable binding pair, and
- determining the presence or amount of the labeled binding pair or the free labeled binding partner of a specific binding pair as a measure of the presence or concentration of the ligand in the sample.
- 16. The method according to claim 15, wherein the ligand is a high molecular weight ligand.
- 17. The method according to claim 16, wherein the ligand is selected from the group consisting of a virus, virus marker, tumor marker, and a hormone.
- 18. The method according to claim 15, wherein said binding partner of a specific binding pair is selected from the group consisting of antigens, antibodies, and antibody fragments.
- 19. The method according to claim 15, wherein the at least one binding partner carries an enzymatic or electrochemiluminescent label.
- 20. The method according to claim 15, wherein the at least one specific binding partner has a second specific binding site for a solid phase-bound binding partner.
- 21. The method according to claim 20, wherein the at least one binding partner is biotinylated and capable of binding to a streptavidin surface.
- 22. A method for reducing nonspecific interference in an immunoassay which uses at least one buffer, comprising adding a protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H or PO.sub.3 H.sub.2 groups wherein said protein aggregate is an aggregate of albumin, to a buffer used in said immunoassay.
- 23. A method for preparing an interference-reducing substance, comprising the steps of a) polymerizing a protein to form an aggregate, and b) acylating the protein aggregate with ah acylating agent wherein the protein is albumin.
- 24. The method according to claim 23, wherein the protein is thermally polymerized.
- 25. The method according to claim 23, wherein the protein aggregate is acetylated with acetyl-o-succinimide or with succinic acid anhydride.
- 26. A kit for decreasing nonspecific interactions in an immunoassay, comprising (a) a protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H and PO.sub.3 H.sub.2, and (b) a buffer wherein said protein aggregate is an aggregate of albumin.
- 27. The kit according to claim 26, further comprising at least one binding partner specific for a high molecular weight ligand to be detected in said immunoassay.
- 28. The kit according to claim 27, wherein said binding partner is detectably labeled.
- 29. The kit according to claim 28, further comprising at least one unlabeled binding partner specific for a high molecular weight ligand to be detected.
- 30. A test strip for detecting a ligand, comprising a specific binding partner and a protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H and PO.sub.3 H.sub.2 ; wherein said specific binding partner, said protein aggregate or both said specific binding partner and said protein aggregate are reversibly impregnated on different layers wherein said protein aggregate is an aggregate of albumin.
- 31. A test strip for detecting a ligand, comprising a specific binding partner and a protein aggregate which is acylated with --CO--R groups, wherein R is a branched or unbranched C.sub.1-4 alkyl residue which is unsubstituted or substituted with - a member selected from the group consisting of carboxy, hydroxy, SO.sub.3 H and PO.sub.3 H.sub.2 ; wherein said specific binding partner and protein aggregate are, reversibly impregnated on the same layer which is fixed on a carrier wherein said protein aggregate is an aggregate of albumin.
Priority Claims (1)
Number |
Date |
Country |
Kind |
43 43 479.7 |
Dec 1993 |
DEX |
|
Parent Case Info
This application is a rule 371 continuation of PCT/EP94/04264 filed Dec. 21, 1994.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP94/04264 |
12/21/1994 |
|
|
8/21/1995 |
8/21/1995 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO95/17668 |
6/29/1995 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5051356 |
Warren, III et al. |
Sep 1991 |
|
5077198 |
Shih et al. |
Dec 1991 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
A2 0269 092 |
Jun 1988 |
EPX |
A3 0 347 138 |
Dec 1989 |
EPX |
0 525 916 A1 |
Feb 1993 |
EPX |